A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.
A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.
To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
Inclusion Criteria:
Exclusion Criteria:
Bruxelles - Brussel, 1200, Belgium
Beijng, 100142, China
Homburg/Saar, Saarland 66421, Germany
Athens / Greece, 115 27, Greece
Kashiwa-shi, Chiba 277-8577, Japan
Osakasayama-shi, Osaka 589-8511, Japan
Bunkyo-ku, Tokyo 113-8655, Japan
Chuo-ku, Tokyo 104-0045, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Minato-ku, Tokyo 105-8470, Japan
Shibuya-ku, Tokyo 150-8935, Japan
Shinjuku-ku, Tokyo 162-8666, Japan
Jeollabuk-do, 561-712, South Korea
Cruces/Barakaldo, Bilbao 48903, Spain
Kaohsung, 833, Taiwan